SCHEMBL6507250

SCHEMBL6507250

CCCC(C)c1c(CC)nn2c(-c3ccc(OC)cc3C)ccnc12

nearest known ligand 0.50

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 8/20 0.48
MAPT P10636 2/20 0.41
THRB P10828 1/20 0.39
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CRH P06850 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6504878 0.89 CRHR1 (0.49) CRHR1MAPTTHRBCRH
SCHEMBL6504492 0.88 MAPT (0.37) CRHR1MAPTTHRBCRH
SCHEMBL6505219 0.87 CRHR1 (0.48) CRHR1MAPTTHRB
SCHEMBL6495620 0.82 MAPT (0.44) CRHR1MAPTTHRBTDP1CRH
SCHEMBL6505224 0.80 CRHR1 (0.50) CRHR1MAPTTHRBTDP1L3MBTL1
SCHEMBL6504826 0.79 CRHR1 (0.39) CRHR1CRH
SCHEMBL6496020 0.79 MAPT (0.37) CRHR1MAPTTHRBCRH
SCHEMBL6505240 0.78 NPC1 (0.46) CRH
SCHEMBL6495325 0.73 CRHR1 (0.41) CRHR1MAPTTHRBL3MBTL1CRH
SCHEMBL6504656 0.73 NPC1 (0.43) CRHR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6958341-B2 Pyrazolopyrimidines as CRF antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-10-25 US claimed
US-6958341-B2 Pyrazolopyrimidines as CRF antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-10-25 US disclosed
US-20030139426-A1 Pyrazolopyrimidines as CRF antagonists WILDE RICHARD G (US) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139426-A1 Pyrazolopyrimidines as CRF antagonists CRHR1, CRHR2, CRH CRHR1 1/4885MAPT 2933/4885THRB 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.